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Abstract The incidence and prevalence of older adults
living with HIV infection is increasing. Recent reports of
increased neuropathologic and metabolic alterations in
older HIV? samples, including increased cortical beta-
amyloid, have led some researchers to suggest that aging
with HIV may produce a neuropsychological proﬁle akin to
that which is observed in ‘‘cortical’’ dementias (e.g.,
impairment in memory consolidation). To evaluate this
possibility, we examined four groups classiﬁed by HIV
serostatus and age (i.e., younger B40 years and older
C50 years): (1) Younger HIV- (n = 24); (2) Younger
HIV? (n = 24); (3) Older HIV- (n = 20); and (4) Older
HIV? (n = 48). Main effects of aging were observed on
episodic learning and memory, executive functions, and
visuoconstruction, and main effects of HIV were observed
on measures of verbal learning and memory. The interac-
tion of age and HIV was observed on a measure of verbal
recognition memory, which post hoc analyses showed to be
exclusively attributed to the superior performance of the
younger HIV seronegative group. Thus, in this sample of
older HIV-infected individuals, the combined effects of
HIV and aging do not appear to result in a ‘‘cortical’’
pattern of cognitive deﬁcits.
Keywords Human immunodeﬁciency virus  Aging 
Cognition  Neuropsychological tests  Episodic memory
Introduction
Since the introduction of combined antiretroviral therapies
(cART) in 1996, the mortality rates associated with HIV
infection and AIDS have decreased dramatically [1]. As a
consequence, a larger proportion of individuals infected
with HIV are living into increasingly later years of adult-
hood. At the same time, the number of incident HIV
infection cases among older adults continues to grow,
accounting for approximately 15% of new HIV diagnoses
in 2005 [1]. These convergent factors have signiﬁcantly
increased the prevalence of older adults living with HIV
infection over the past decade; at present, approximately
27% of HIV-infected persons are aged 50 years and older
[2]. In the United States, older adults currently represent
29% of AIDS cases [1], with prevalence rates estimated to
rise above 50% by 2015 [3]. Although controversy remains
regarding the impact of aging on HIV disease outcomes
[4], older HIV-infected adults may experience greater
premorbid immune down-regulation [5], more rapid dis-
ease progression [6], and higher morbidity rates [7] than
younger individuals.
Independent of one another, HIV and aging are each
associated with signiﬁcant neuropathological alterations
(e.g., reduced synaptodentritic complexity). Increasing
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risk factors may have additive or synergistic effects on the
central nervous system (CNS). Moreover, the neuropatho-
logical alterations associated with aging and HIV both
preferentially affect the structure and function of prefonto-
striato-thalamo-cortical circuits and temporolimbic net-
works [8, 9]. For example, several studies have found
increased amyloid deposition in the hippocampus and
frontal lobes in older HIV-infected individuals [10, 11],
and older age has been associated with increased preva-
lence of ubiquitinated proteins in the temporal lobe white
matter at autopsy, perhaps indicating synaptodendritic
injury, inﬂammatory mechanisms, and gliosis [12]. Recent
neuroimaging studies in HIV also indicate that older age is
associated with disproportionate frontal systems altera-
tions, including smaller frontal grey matter volumes [13],
elevated markers of glial activation in frontal white matter
(e.g., myo-inositol) [14], and reduced neuronal integrity (as
measured by levels of N-acetylaspartate) in the basal gan-
glia [14], areas long recognized as being highly vulnerable
to HIV-associated neuropathologies [15]. Together, the
presence of these neuropathologic and metabolic altera-
tions suggests that increased cerebral and subcortical
damage may be evident in older HIV-infected individuals,
thereby amplifying the risk of neurocognitive impairment
[16].
Although the conceptual commonalities between the
neuropsychological proﬁles of aging and HIV infection
were ﬁrst described over 20 years ago [17], only recently
have investigators begun to elucidate the combined effects
of these risk factors on cognition. Older adults infected
with HIV are more likely than their younger counterparts to
develop HIV-associated neurocognitive disorders (HAND),
including HIV-associated dementia (HAD) and HIV-asso-
ciated minor neurocognitive disorder (MND) [18–21].
Valcour et al. [19] reported that HIV-infected individuals
aged 50 years and older had a three-fold increased risk of
HAD as compared to younger adults with HIV, even after
controlling for other demographic characteristics, HIV
disease severity, psychiatric comorbidities, and cART use.
Nondemented older adults with HIV also evidence milder
forms of neuropsychological impairment at disproportion-
ately higher levels [cf. 22], particularly in the domains of
episodic memory, executive functions, and psychomotor
speed [23, 24].
With the advancing age of the HIV population, greater
attention has also been paid to additional conditions that
have the potential to affect cognition and whose risk
increases with age. For example, the aging process itself is
oftentimes accompanied by a host of medical and neuro-
logical conditions including hypertension, elevated choles-
terol and triglyceride levels, cerebrovascular comorbidity
(e.g., stroke), and metabolic dysregulation (e.g., insulin
resistance), all of which may be accelerated in the setting of
HIV infection [25–27]. Some researchers have also postu-
lated that, in the context of aging, HIV infection may lead to
increased rates of neurodegenerative disease by lowering
the threshold for clinical manifestations of such disorders,
via axonal injury or other mechanisms, in accordance with
the cerebral reserve hypothesis [28, 29]. One frequently
offered hypothesis is that older HIV-infected individuals
may have an ampliﬁed risk of developing Alzheimer’s dis-
ease [30–32] or evidence neurocognitive results similar to
an Alzheimer’s presentation (e.g., a ‘‘cortical’’ pattern of
cognitive deﬁcits), with ﬁndings of increased levels of brain
beta amyloid and plaque-like lesions in older HIV? cohorts
supporting this hypothesis [10, 11, 33, 34, cf. 12].
With this complex combination of risk factors, some
researchers have suggested that the development and
expression of HAND may be evolving in older adults with
HIV [28, 29, 31]. In other words, older HIV? adults may
display a qualitatively different expression of HAND from
that which is observed in younger and middle-aged adults,
who typically display a ‘‘subcortical’’ cognitive proﬁle of
bradykinesia, bradyphrenia, executive dysfunction, and
deﬁcient memory encoding and retrieval [35, 36]. More
speciﬁcally, older adults with HAND may be more vul-
nerable to cortical dysfunction and more likely to show
deﬁcits typically associated with temporal (e.g., rapid for-
getting, dysnomia) and parietal lobe functioning [31],
especially given the aforementioned neuropathological
alterations in mediotemporal structures that are associated
with aging [10, 12]. This possibility may be even more
likely considering the shifting pattern of neurocognitive
disorders that may already be occurring in the cART era
[37, 38]. To this end, recent studies have shown dysfunc-
tion in mediotemporal regions on positron emission
tomography scans [31] and functional magnetic resonance
imaging (fMRI) during memory encoding and retrieval
[39], as well as cortical thinning in primary sensorimotor,
premotor, and visual areas [40].
Despite the growing popularity of this hypothesis, no
study to our knowledge has speciﬁcally tested the possi-
bility of HAND evolving to reﬂect increased ‘‘cortical’’
neuropsychological deﬁcits by examining potential inter-
actions between aging and HIV with appropriate age and
HIV comparison participants, as has been recommended
[41, 42]. We therefore attempted to investigate the pattern
of deﬁcits in an older HIV seropositive sample in com-
parison to three other groups: (1) an older HIV seronega-
tive sample; (2) a younger HIV seropositive sample; and
(3) a younger HIV seronegative sample. We hypothesized
that there would be signiﬁcant main effects of HIV sero-
status and age on measures of episodic learning and
memory and executive functions, as well as main effects of
age on semantic knowledge. In addition, we hypothesized
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123that a signiﬁcant interaction would be observed between
HIV and age on neuropsychological measures of episodic
learning and memory, semantic knowledge, and visuospa-
tial functioning.
Methods
Participants
The study sample included 116 participants who were
classiﬁed with respect to HIV serostatus (HIV- and
HIV?) and age (i.e., younger B40 years and older
C50 years). This yielded four groups: (1) Younger HIV-
(n = 24); (2) Younger HIV? (n = 24); (3) Older HIV-
(n = 20); and (4) Older HIV? (n = 48). Although the
‘‘older’’ adults represent a relatively youthful cohort (ran-
ge = 50–79 years) in comparison to the cognitive aging
literature, the use of 50 years as the cutoff age was
informed both by the nature of current HIV epidemic [1]
and NIMH neuroAIDS research recommendations [42].
Participants were recruited from local HIV clinics and
community organizations from 2005 to 2008. HIV sero-
status was determined by enzyme linked immunosorbent
assays and conﬁrmed by a Western Blot test. Study
exclusion criteria included: (1) severe psychiatric illness
(e.g., schizophrenia); (2) neurological disease (e.g., seizure
disorders, closed head injuries with loss of consciousness
greater than 15 min, and CNS neoplasms or opportunistic
infections); (3) an estimated verbal IQ score less than 70 on
the Wechsler Test of Adult Reading (WTAR) [43]; (4)
substance dependence within 6 months of evaluation; and
(5) a urine toxicology screen positive for illicit drugs (other
than marijuana) on the day of evaluation. Note that, a
positive marijuana toxicology screen was not grounds for
exclusion because drug metabolites are detectable up to
30 days after last use and several medications commonly
used in HIV (e.g., efavirenz, marinol) can produce positive
toxicology screens.
Regarding the demographic characteristics of the study
samples, Table 1 shows that the two Younger groups were
comparable in age, as were the two Older groups. How-
ever, both HIV? groups achieved fewer years of education
and contained a smaller proportion of women compared to
the Younger HIV seronegative group (Ps\0.05). In
addition, the Older HIV? group obtained lower scores on
the HIV Dementia Scale (HDS) [44] compared to the other
three samples, which is consistent with prior research [19].
Finally, the HIV? groups had signiﬁcantly higher pro-
portions of individuals with lifetime diagnoses of major
depression and displayed a trend-level (P\0.10) differ-
ence in current affective distress as compared to the HIV-
groups. As concerns the general medical characteristics of
the samples, Table 2 shows that the Older HIV? group had
the highest prevalence of hepatitis C infection, a trend-
level (P\0.10) difference in hypercholesterolemia, and,
along with the Older HIV- group, also had higher rates of
hypertension. Table 2 also shows that the Younger and
Older HIV? groups did not differ in terms of cART status,
HIV CSF RNA viral loads, or current CD4 lymphocyte
counts (all P values[0.10), although the Older HIV?
group had a lower nadir CD4 count (P\0.05) and the
Younger HIV? group evidenced trends for having both a
higher median viral load and a higher proportion of
Table 1 Demographic and psychiatric characteristics of the study sample
Younger HIV-
(n = 24)
Older HIV-
(n = 20)
Younger HIV?
(n = 24)
Older HIV?
(n = 48)
F/v
2 P
Demographic characteristics
Age (years) 30.1 (7.1) 56.6 (6.3) 34.3 (5.0) 55.5 (6.4) 135.21 \0.001 Y
- = Y
?\O
- = O
?
Education (years) 15.4 (2.4) 14.5 (2.3) 13.4 (2.8) 13.6 (2.8) 3.15 0.028 Y
-[Y
?,O
?
WTAR verbal IQ 108.3 (9.8) 105.1 (10.2) 100.8 (13.4) 102.6 (14.1) 1.69 0.174 –
HIV Dementia Scale 15.8 (0.5) 15.5 (0.9) 15.6 (0.9) 14.3 (3.0) 3.77 0.01 O
?\O
-,Y
-,Y
?,
Sex (% female) 66.7% 40.0% 16.7% 20.8% 18.92 \0.001 Y
-[Y
?,O
?
Ethnicity (% Caucasian) 50.0% 50.0% 33.3% 62.5% 18.00 0.115 –
Psychiatric characteristics
Major depression
a 25.0% 25.0% 50.0% 56.3% 9.73 0.021 Y
? = O
? [O
- = Y
-
Generalized anxiety
a 0.0% 5.0% 8.3% 8.5% 2.29 0.514 –
Substance dependence
a 25.0% 40.0% 54.2% 50.0% 5.36 0.148 –
POMS total 41.6 (24.2) 44.9 (28.6) 62.8 (33.0) 48.3 (26.6) 2.53 0.064 –
POMS Proﬁle of Mood States, WTAR Wechsler Test of Adult Reading, Y
- Younger HIV seronegative, O
- Older HIV seronegative, Y
? Younger
HIV seropositive, O
? Older HIV seropositive
a Denotes a lifetime diagnosis
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123detectable plasma viral load (Ps\0.10). As might be
expected, the Older HIV? group had a longer duration of
infection and a higher prevalence of AIDS diagnoses than
the Younger HIV? group.
Materials and Procedure
All participants provided written, informed consent prior to
completing a comprehensive medical, psychiatric, and
neuropsychological research evaluation for which they
received ﬁnancial compensation. The study was approved
by the university’s human subjects committee.
Neuropsychological Assessment
All participants were administered a comprehensive neu-
ropsychological assessment battery by trained research
assistants. The WTAR was administered as an estimate of
premorbid verbal intellectual functioning. Measures for
analysis were selected from the larger battery that were
known to be the most sensitive tests to cortical dysfunction,
in the domains of episodic memory, semantic knowledge,
executive functions, and visuospatial functioning. These
measures included (1) the Boston Naming Test (BNT) [45]
a standardized category (animals) verbal ﬂuency test
(Category Fluency) [46]; (2) the Famous Faces subtest of
the Kaufman Adolescent and Adult Intelligence Test
(KAIT) [47]; (3) the Logical Memory subtest from the
Wechsler Memory Scale, 3rd edition (WMS-3) [48]; (4)
the California Verbal Learning Test, 2nd edition (CVLT-II)
[49]; (5) the Boston Qualitative Scoring System (BQSS)
for the Rey–Osterrieth Complex Figure [50]; (6) Trail-
making Test, Part B [51]; and (7) Tower of London Test
(Drexel Version) [52]. Table 3 indicates the speciﬁc vari-
ables that were analyzed from each measure. We also
classiﬁed each individual into one of three memory proﬁles
using a discriminant function algorithm based on three
CVLT-II variables. This algorithm was originally derived
for the ﬁrst version of the CVLT [53] and classiﬁes indi-
viduals as having a CVLT-II proﬁle indicating an encod-
ing/storage deﬁcit, a retrieval deﬁcit, or a normal proﬁle.
The utility of this algorithm has been shown in a number of
studies examining the pattern of memory performance in
various neurological groups, including HIV [54–56].
Psychiatric Assessment
All participants underwent a structured psychiatric assess-
ment using the Composite International Diagnostic Inter-
view (CIDI version 2.1) [57] to generate lifetime diagnoses
of Major Depressive Disorder (MDD), Generalized Anxi-
ety Disorder (GAD), and Substance-Related Disorders per
Diagnostic and Statistical Manual of Mental Disorders
(4th ed.) [58] criteria. The Proﬁle of Mood States (POMS)
[59] was administered to assess overall acute (i.e., the week
prior to evaluation) affective distress. The POMS is a
Table 2 HIV disease and medical characteristics of the study samples
Younger HIV-
(n = 24)
Older HIV-
(n = 20)
Younger HIV?
(n = 24)
Older HIV?
(n = 48)
v
2 P
Medical characteristics
Hepatitis C 4.2% 0.0% 4.2% 25.5% 13.50 0.004 O
?[Y
-,Y
?,O
-
Hypertension 8.3% 60.0% 25.0% 41.7% 15.08 0.002 O
- = O
?[Y
-,Y
?
Hypercholesterolemia 0.0% 0.0% 0.0% 10.4% 7.40 0.060 –
Diabetes mellitus 0.0% 10.0% 4.2% 10.4% 3.28 0.350 –
HIV disease characteristics
AIDS (%) – – 37.5% 68.8% 6.43 0.011 O
?[Y
?
HAART (%) – – 66.7% 75.0% 1.75 0.416 –
ARV regimen duration (months) – – 29.4 (51.8) 12.9 (20.3) 1.54 0.216 –
HIV duration (years) – – 9.6 (6.7) 15.6 (7.0) 9.63 0.002 O
?[Y
?
Nadir CD4
a (cells/ll) – – 253 [185, 344] 102 [29, 282] 4.88 0.027 Y
?[O
?
Current CD4
a (cells/ll) – – 640 [299, 916] 512 [253, 693] 0.85 0.358 –
Plasma HIV RNA
a (log10) – – 1.9 [1.7, 4.1] 1.7 [1.7, 1.8] 2.73 0.098 –
CSF HIV RNA
a,b (log10) – – 1.7 [1.7, 1.8] 1.7 [1.7, 1.7] 0.18 0.670 –
% Detectable plasma HIV RNA – – 45.8% 23.9% 3.52 0.061 –
% Detectable CSF HIV RNA – – 20.0% 16.1% 0.11 0.745 –
Y
- Younger HIV seronegative, O
- Older HIV seronegative, Y
? Younger HIV seropositive, O
? Older HIV seropositive
a Data represent medians with interquartile ranges in brackets
b O
? n = 31 and Y
? n = 15
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12365-item, self-report measure of current mood states on
which participants rate various adjectives (e.g., ‘‘unhappy’’)
on a ﬁve-point Likert-type scale ranging from 0 (‘‘not at
all’’) to 4 (‘‘extremely’’). The POMS Total Mood score was
used for all analyses.
Medical Assessment
Finally, all participants received a neuromedical evalua-
tion, which included a comprehensive review of medica-
tions, medical history and current symptoms, a complete
physical and neurological evaluation, CDC staging, and the
HDS, which is a general cognitive screening tool that
evaluates memory, attention, psychomotor speed, and
construction (range = 0–16). Participants also underwent a
blood draw and lumbar puncture (HIV? n = 46). Standard
ﬂow cytometry methods were used to count CD4? lym-
phocytes in blood samples. Plasma and CSF HIV RNA
levels were quantiﬁed using RT-PCR (Amplicor, Roche
Diagnostics, Indianapolis, IN).
Data Analyses
Power analyses showed that the study was adequately
powered ([0.80) to detect interactions of medium-to-large
effect sizes, using a critical alpha at 0.05, based on our
sample size (N = 116). The data were screened for sig-
niﬁcant outliers (i.e., data points[3.5 SD from the overall
group mean) and evaluated for normality (i.e., Shapiro–
Wilk W test, P\0.05). A series of 2 9 2 ANOVAs were
run to test for main effects of age (dichotomous, B40 vs.
C50 years) and HIV status (dichotomous) and the potential
interaction between the two variables on the neuropsy-
chological scores of interest. Raw neuropsychological test
scores were used for all analyses. To evaluate the possible
effects of confounding variables on the hypothesized
effects, a series of follow-up linear regressions were per-
formed in which the four-level aging and HIV grouping
variable was used as a predictor of the neuropsychological
test scores, alongside the demographic, psychiatric, and
medical variables upon which omnibus group differences
Table 3 Neuropsychological test performance in the four study samples
HIV- HIV? Effects (F values)
Young
(n = 24)
Old
(n = 20)
Young
(n = 24)
Old
(n = 48)
HIV Aging HIV 9
Aging
Boston Naming Test (total) 55.25 (4.63) 55.55 (4.57) 53.77 (5.66) 55.00 (5.05) 0.91 0.39 0.27
KAIT Famous Faces 12.71 (3.99) 14.60 (3.33) 9.80 (3.99) 13.75 (4.63) 4.91* 11.31** 1.44
Animal ﬂuency 22.75 (5.34) 20.47 (4.33) 21.50 (5.35) 20.77 (5.26) 0.62 1.56 0.81
WMS-3 Logical Memory
I Total 45.29 (14.61) 48.65 (7.76) 41.50 (10.12) 38.62 (11.70) 9.38** 0.19 1.89
II Total 33.12 (7.33) 29.95 (7.16) 24.29 (8.32) 22.21 (8.92) 24.79** 1.72 0.17
Recognition 26.92 (2.06) 27.25 (1.68) 24.96 (2.69) 25.04 (2.86) 16.15** 0.10 0.10
% Retained 90.71 (9.09) 85.70 (13.23) 80.88 (16.96) 78.29 (19.25) 6.91** 1.20 0.33
CVLT-II
Total 1–5 58.83 (9.19) 51.05 (9.75) 50.63 (12.77) 46.51 (11.99) 9.29** 4.96* 1.54
Total Cued Recall Intrusions 0.29 (0.69) 1.35 (1.57) 2.58 (2.62) 2.91 (4.09) 10.18** 1.23 0.65
Long Delay Free Recall 13.13 (2.13) 10.45 (2.46) 10.17 (4.35) 9.30 (4.13) 9.79** 3.95* 2.31
Recognition Discriminability 3.69 (0.36) 2.77 (0.71) 2.86 (0.94) 2.78 (0.95) 7.15** 7.37** 9.95**
Rey-O BQSS
Copy Presence and Accuracy 18.08 (1.42) 17.05 (2.16) 17.92 (2.12) 17.35 (1.77) 0.01 3.15 1.65
Immediate Recall Presence and Accuracy 14.20 (3.16) 11.40 (2.39) 13.08 (3.02) 10.98 (3.45) 2.49 9.40** 1.20
Delayed Recall Presence and Accuracy 13.83 (2.85) 10.70 (3.79) 12.96 (3.68) 10.98 (3.41) 1.36 11.28** 1.71
Delayed Retention -1.50 (10.36) -1.40 (16.23) -2.96 (17.57) 2.44 (27.61) 1.36 0.51 0.38
Trailmaking Test, Part B (time) 46.75 (16.10) 69.45 (17.94) 57.25 (22.57) 80.58 (52.94) 2.44 7.28** 0.03
Tower of London (Drexel) Total Moves 24.83 (13.16) 37.95 (18.56) 27.63 (17.44) 26.83 (19.65) 1.25 2.34 3.21
Note: All data are raw scores
BQSS Boston Qualitative Scoring System, CVLT-II California Verbal Learning Test, Second Edition, KAIT Kaufman Adolescent and Adult
Intelligence Test, Rey-O Rey–Osterrieth Complex Figure, WMS-3 Wechsler Memory Scale, 3rd Edition
* P\0.05; ** P\0.01
AIDS Behav (2011) 15:1187–1196 1191
123were observed (see Tables 1, 2). The critical alpha level
was set at 0.05 for all analyses.
Results
As shown in Table 3, main effects of age were observed on
select measures of learning (CVLT-II Total 1–5), memory
(KAIT Famous Faces; CVLT-II Long Delay Free Recall
and Recognition Discriminability; and Rey-O BQSS
Immediate Recall and Delayed Recall), executive functions
(Trailmaking Test, Part B), and visuoconstruction (Rey-O
BQSS Copy Presence and Accuracy Score).
Main effects of HIV were observed on measures of
learning (CVLT-II Total 1–5; WMS-3 Logical Memory I
Total) and memory (KAIT Famous Faces; WMS-3 Logical
Memory II Total, Recognition, and Percent Retained;
CVLT-II Long Delay Free Recall and Recognition Dis-
criminability). There was also a main effect of HIV on the
CVLT-II classiﬁcations (v
2 (2) = 9.56, P = 0.008). Full
results of the classiﬁcation using the CVLT-II discriminant
function algorithm are presented in Table 4.
As shown in Table 3, an interaction effect was observed
on a measure of verbal recognition memory (CVLT-II
Recognition Discriminability). However, post hoc analyses
revealed that this interactive effect was exclusively attrib-
utable to the superior performance of the younger HIV-
group, such that the younger HIV- comparison group was
signiﬁcantly different from the other three groups, who
were all roughly equivalent.
Post hoc analyses revealed no interpretive changes in the
signiﬁcance level of any HIV/aging interaction term when
medical (e.g., hypertension, hepatitis C infection), psychi-
atric (e.g., depression), or demographic (i.e., sex and edu-
cation) factors were included as covariates in the statistical
models.
Discussion
With the advancing age of the HIV? population and
improved outlook for longevity in individuals with HIV
infection, a number of clinical researchers have recently
considered whether aging in the setting of HIV might
confer additional neurocognitive risks than either condition
in isolation. While it is clear that HIV and aging each
contribute independent deleterious effects on the CNS,
resulting in decreased cognitive functioning in a subset of
individuals, indirect lines of evidence have also suggested
that HIV might lower the threshold for additional neuro-
degenerative processes that are usually seen at a later age
outside of the context of HIV. While some studies have
focused on enhanced cerebrovascular [26] and metabolic
[27] risk in older HIV populations, the theories that have
seemingly garnered the most attention recently have
focused on the potential altered expression of HAND in
older adults, which may reﬂect increased neocortical neu-
ropathology or dysfunction, or even an early Alzheimer’s
process [28]. Given the promulgation of these theories, we
sought to examine whether there might be detectable
changes in the neuropsychological proﬁle of older indi-
viduals with HIV infection that might provide behavioral
evidence to support (or challenge) these theories.
In the present study, our ﬁndings converge with prior
data showing that older age and HIV infection indepen-
dently increase the risk for neurocognitive impairment,
particularly in the areas of episodic learning and memory
and executive functions. However, the combined effects of
HIV and aging did not reﬂect what would classically be
considered a ‘‘cortical’’ pattern of cognitive deﬁcits. To this
end, interaction effects were only found on a measure of
verbal recognition memory, and these effects were exclu-
sively due to the superior performance of the younger
HIV- participants. Our ﬁndings, while preliminary, sug-
gest that, even with potential changes in underlying neu-
ropathology (e.g., brain beta amyloid deposition), older
HIV-infected persons may not display neuropsychological
deﬁcits that appear ‘‘cortical’’ in nature compared to what
might otherwise be expected in HIV disease and aging
alone.
Given the often subtle effects of such neuropathological
changes on cognition and the relative youth of our sample
in comparison to the aging literature, it could be argued
that the effects expected on neuropsychological test results
in this study would be more likely to fall within the small-
to-medium range. By this line of reasoning, having ade-
quate statistical power for medium-to-large effect sizes
may not be sufﬁcient. However, we set a somewhat liberal
alpha level in order to diminish this possibility, thereby
decreasing our risk for Type II error (and inﬂating our Type
I error risk). An even more liberal alpha value of 0.10
would result in one additional signiﬁcant interactive effect
on Tower of London Total Moves. Yet this result, sur-
prisingly, was due to the poor performance of the older
HIV seronegative sample, while the other three groups
were equivalent.
Table 4 California Verbal Learning Test-II discriminant function
classiﬁcation results in the four study samples
Encoding/storage
proﬁle (%)
Retrieval
proﬁle (%)
Normal
proﬁle (%)
HIV- Young 0.0 16.7 83.3
HIV- Old 15.0 10.0 75.0
HIV? Young 25.0 20.8 54.2
HIV? Old 17.0 23.4 59.6
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aging in this sample, it is still unclear whether the com-
bination of these factors confers an additive risk of neu-
rocognitive impairment. While some prior studies have
found additive effects in older HIV? samples [19, 24], the
proﬁle of neuropsychological tests in our sample did not
necessarily reﬂect an additive effect, although we did not
explicitly test for additivity given the speciﬁc hypotheses
being evaluated in this study. However, individuals in the
older HIV? group scored signiﬁcantly lower on the HDS, a
screening instrument designed speciﬁcally for the detection
of HIV-associated dementia, suggesting potential additive
effects. In addition, it should be noted that we did not
examine a number of other cognitive domains that might be
expected to show additive effects of HIV and aging, such
as psychomotor/processing speed and working memory. Of
note, these domains may be particularly important to
examine in investigating the effect of other comorbidities
on the proﬁle of cognitive deﬁcits in older HIV? samples.
For example, emerging evidence suggests that cerebro-
vascular risk factors associated with aging and HIV con-
tribute signiﬁcantly to performance on neurocognitive tests
of psychomotor and processing speed [60], especially
among individuals pharmacologically untreated for these
risks [61]. Thus, it will be important to address issues of
additivity and comorbidity in future studies of aging in the
context of HIV, as added risk factor burden may increase
the risk of functional impairment, including medication
nonadherence [62].
The combined effects of HIV and advancing age raise
clinically relevant questions regarding the effective diag-
nosis and treatment of neurocognitive symptoms in HIV
infection, especially with the likelihood of additive dele-
terious effects [23]. The possibility that concomitant neu-
rodegenerative processes are superimposed upon this
clinical syndrome has the potential to challenge current
models of diagnosis and treatment of HAND in older
individuals. However, in this sample of older HIV? indi-
viduals, we found minimal evidence for qualitatively dis-
tinct cognitive impairment due to alternative etiologies.
Thus, clinicians and researchers may need to have sufﬁ-
cient cause to broaden their differential diagnosis to
include other neurodegenerative causes in most individuals
under 65 who are on cART treatment and have well con-
trolled disease (i.e., adequate plasma and CSF viral con-
trol). This does not deny that some HIV? individuals may
experience comorbid processes associated with normal
aging (e.g., cerebrovascular risk) that may be detrimental
to their neurological health, although the extent to which
HIV impacts this presentation remains uncertain. It is also
still unclear what additional risk older HIV? individuals
with poorer disease management or additional risk factors
(e.g., substance abuse) face.
A few limitations to this study suggest important ave-
nues for future study. First, although the age of our older
HIV? group (mean = 55.4 years) is commensurate with
other studies of aging in HIV [24], our sample was still
relatively young in comparison to most studies of aging
outside of the context of HIV. It is possible that as HIV-
infected individuals advance in age beyond the range rep-
resented by our sample, their risk for cerebrovascular
co-pathology and immune dysregulation may increase,
especially with extended use of cART medications, which
may result in a different pattern of cognitive impairment.
The absence of interactive effects in this sample also raises
the possibility that a lag occurs between when neuro-
pathological markers appear in the cortex and when
changes can be observed on neuropsychological tests. For
example, it is clear that the underlying neuropathology of
Alzheimer’s disease is laid down many years prior to the
emergence of clinical symptoms [63], and future studies
using an epidemiological approach may show that age and
HIV interact in older HIV? individuals to lower the age of
onset for Alzheimer’s disease. However, in the case of
amyloid-beta, there may be important differences in its
neuropathology in HIV versus Alzheimer’s disease [64]
that result in unpredictable effects on the neuropsycho-
logical proﬁle of HAND in older adults. Future studies
should examine a sample of HIV? individuals at later ages
in order to further expand on these possibilities, perhaps
using neuroimaging techniques that are sensitive to subtle
changes in microstructure [65, 66].
Second, our study may have suffered from survival bias,
in that our older HIV? cohort may have contained a larger
proportion of long-term non-progressors or individuals
with slower HIV progression, whereas post-mortem studies
that have reported increased neuropathology in older
HIV? individuals may have included a larger proportion of
participants susceptible to dementia (and with worse
immunological health). To this end, despite having a lower
nadir CD4 count, a longer duration of infection, and an
increased likelihood of having AIDS, our older HIV?
cohort had similar current disease markers (e.g., current
CD4) compared with the younger HIV? group, suggesting
adequate current viral suppression. Thus, it would be ideal
to examine a subgroup of older HIV? individuals with a
shorter duration of infection to examine the interaction of
aging and HIV in those with different patterns of pro-
gression. However, our older HIV? sample only contained
6 participants with duration of infection less than 5 years.
Therefore, in an attempt to partially address this issue, we
performed post hoc correlational analyses in the older
HIV? group between duration of infection and our neu-
ropsychological outcomes. These analyses revealed that the
Boston Naming Test (r = 0.58; P\0.0001), KAIT
Famous Faces Test (r = 0.38; P = 0.01), and BQSS
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were signiﬁcantly and positively associated with duration
of infection in this group. Thus, a shorter duration of
infection is correlated with lower neuropsychological per-
formances on some measures traditionally associated with
a ‘‘cortical’’ proﬁle of deﬁcits in older HIV? individuals,
which is suggestive of a differential pattern of deﬁcits in
older HIV? individuals with shorter durations of infection.
Nonetheless, this ﬁnding is preliminary and awaits more
detailed future analyses.
Finally, both of our HIV? groups were relatively healthy
in terms of HIV disease characteristics in comparison to
many community-based samples [7]. It is possible that
cognitive (and pathological) changes may be more likely to
occur in individuals in later disease stages or with worse
current HIV immunological health. Similarly, fewer par-
ticipants evidenced HIV-associated neurocognitive disor-
ders than might be expected—19 participants evidenced
asymptomatic neuropsychological impairment, 6 partici-
pants met criteria for MND, and 1 participant met criteria
for HAD. It may be that a different expression of HAND
only occurs in individuals with more severe levels of cog-
nitive impairment, such as dementia [30], which our sample
failed to provide in large numbers. However, to explore this
possibility, we also conducted post hoc analyses that only
included individuals from the older HIV? group with
HAND diagnoses (n = 15). These analyses resulted in an
interaction on the Trailmaking Test, Part B (P = 0.004),
such that the Older HIV? group with HAND had signiﬁ-
cantly greater times than the three other groups, and the
Younger HIV- group had faster times than the other three
groups. This ﬁnding gives some indication that older HIV?
individuals with HAND diagnoses may have increased
deﬁcits in executive functions, although these preliminary
results will also need to be conﬁrmed. Therefore, future
studies should examine the pattern of neuropsychological
performance in older HIV? participants who are in later
disease stages or evidence greater levels of HIV-associated
neurocognitive disorders to examine for the possibility of
additional neurocognitive deﬁcits in this population.
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